---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-180820"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:02:01.067654+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Eledon Pharmaceuticals Restates Prior Financials and Reports Q2 2025 Results

## Summary
- Restated financial statements for fiscal years 2023 and 2024 and Q1 2025 due to misclassification of Series X and X1 preferred stock; will reclassify as temporary equity.
- Identified a material weakness in internal control over financial reporting related to accounting for equity instruments; controls and disclosure controls were not effective.
- Reported Q2 2025 net loss of $11.2 million ($0.13 per share) and cash and short-term investments of $107.6 million as of June 30, 2025.
- Updated Phase 1b data for tegoprubart showed mean 12-month eGFR of ~68 mL/min/1.73m²; Phase 2 BESTOW topline expected November 2025.
- Company expects current cash to fund operations to the end of 2026.

## SEC filing metadata
- accession: 0001193125-25-180820
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/0001193125-25-180820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-180820
- JSON: https://secwatch.observer/filing/0001193125-25-180820.json
- Plain text: https://secwatch.observer/filing/0001193125-25-180820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.